Refer a Patient
Have a Patient with DM Who May Be Interested in the Flex Study?
The Flex Study is enrolling approximately 180 adult participants across North America, Europe, and Asia Pacific.
This is a phase 2 study (Part A) that leads to a phase 3 study (Part B). The total duration of participation is between 104 and 128 weeks, depending on which part of the study participants are enrolled in. Both parts consist of a screening period, study treatment period, and open-label extension period. Participants who complete the last visit in the treatment period may have the opportunity to receive the investigational medication in the open-label extension period.
The investigational medication, ravulizumab, is a monoclonal antibody that is being compared to standard of care on reducing symptoms in patients with DM. Participants will be assigned at random to receive either the investigational medication or the placebo. Neither the participant nor the study team will know which study treatment option has been assigned, but in case of an emergency, they can quickly find out. Both the investigational medication and the placebo are administered as IV infusions.
The primary objective of the Flex Study is to evaluate the effectiveness and safety of the investigational medication compared to standard of care on reducing symptoms in adults with DM.